Beijing (AsiaNews) – For the first time, a therapy for blood cancers will be included in China’s national health insurance system.
The decision, announced on Saturday by the National Healthcare Security Administration, will take effect on 1 January 2027. It concerns Carteyva, a product developed by the Shanghai-based biotechnology firm JW Therapeutics.
The treatment, which previously costs 1.29 million yuan (around US$ 150,000) per dose, will now be eligible for partial reimbursement.
Carteyva belongs to the category of CAR-T cell therapies, which harness a patient’s own immune system cells to fight cancer.
The process involves extracting T-lymphocytes from the patient’s blood and genetically modifying them in a laboratory so they can recognise and attack tumour cells.
Once prepared, these cells are infused into the patient, where they can locate and destroy the cancer. The therapy is used for certain types of lymphoma; China approved its first CAR-T product in 2021.
The inclusion of Carteyva in the national reimbursement list could expand access to a treatment that has, until now, been prohibitively expensive for patients.
As of the end of 2025, China’s basic health insurance system covered approximately 1.33 billion people. However, only medical drugs included on the national list are eligible for reimbursement through the public fund; for those excluded, patients must generally bear the full cost.
For years, CAR-T therapies remained outside the scope of national coverage, partly due to an unwritten practice whereby drugs priced above 300,000 yuan were deemed too expensive to qualify for reimbursement.
According to an announcement by JW Therapeutics, the price of its product will be 288,600 yuan, approximately US$ 40,000, starting 1 January 2027.
Last year, Carteyva, along with four other CAR-T therapies, was included in China’s first list of high-cost, innovative medicines eligible for coverage through commercial insurance.
These drugs became candidates for national public coverage after two manufacturers, including JW Therapeutics, initiated negotiations on 6 September to have their products integrated into the public system.
“Two or three years ago, we wouldn’t have dared to imagine this,” said Tian Feng, JW Therapeutics chairman and CEO, speaking to The Paper.
The use of these therapies in China remains far less frequent than in the United States or Europe, Sixth Tone reports.
For large B-cell lymphoma, the use of these treatments following the failure of an initial line of therapy is approximately six times lower in China than in the United States.
When administered after the failure of two prior lines of therapy, the gap is even wider: the use of these treatments in China is roughly ten times lower than in the United States and Europe.
This is due, beyond the high cost, to the fact that these therapies require a personalised manufacturing process for each patient, as well as hospitals equipped with specialised staff capable of managing the specific side effects associated with the treatment.
The new national reimbursement list includes a total of 107 medications intended for the treatment of cancers, chronic diseases, mental health disorders, rare conditions, and paediatric diseases.
A separate list, covering commercial insurance and drugs excluded from the basic healthcare system, includes 12 new treatments.
According to Tian Feng, the inclusion of Carteyva marks “a historic moment for lymphoma patients in China,” which has approximately 101,500 new cases every year.
Upon receiving the news, “everyone felt that the treatment of these patients had entered a new and promising phase,” JW Therapeutics’s chairman added.



















